Bora Pharmaceuticals

Historical price data

Bora Pharmaceuticals has established itself as a premier hybrid CDMO and pharmaceutical developer in Asia, achieving significant scale with a market capitalization exceeding $57 billion. The company's strategy successfully integrates high-margin contract services with proprietary drug development, creating a diversified and resilient revenue model. Its core achievements include building PIC/S and FDA-compliant manufacturing facilities, developing a robust pipeline of complex generics and specialty products, and securing a strong position as a critical supply chain partner for multinational pharmaceutical companies.

A vertically integrated platform combining advanced formulation development (complex generics, modified-release) with world-class, multi-dosage-form GMP manufacturing (solids, semi-solids, liquids, and sterile injectables), supported by full analytical and regulatory CMC services.

Bora competes with large Asian CDMOs (e.g., WuXi, Samsung Biologics) on integrated services and regulatory quality, and with global generic pharma companies on complex product development. Its primary differentiators are its unique hybrid business model, high regulatory standards, and strategic location in Taiwan offering a stable operating environment.